Revista espanola de cardiologia最新文献_第3页

La respuesta al levosimendán predice la respuesta a la terapia de modulación de la contractilidad cardiaca: un estudio piloto 对左西孟旦的反应可预测对心脏收缩力调节疗法的反应：一项试点研究

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-08-01 DOI: 10.1016/j.recesp.2024.02.016

引用次数: 0

Mejorando la calidad de la asistencia desde la Sociedad Española de Cardiología. Resultados del programa SEC-Excelente en insuficiencia cardiaca 西班牙心脏病学会提高医疗质量。SEC-Excelente 计划在心力衰竭领域取得的成果。

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-08-01 DOI: 10.1016/j.recesp.2024.02.001

引用次数: 0

Depósitos fibrotrombóticos crónicos: ¿causa o consecuencia de la hipertensión pulmonar? 慢性纤维血栓沉积：肺动脉高压的原因还是结果？

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-08-01 DOI: 10.1016/j.recesp.2023.12.014

引用次数: 0

La dexmedetomidina mitiga la insuficiencia renal aguda tras la cirugía de revascularización coronaria: un ensayo clínico prospectivo 右美托咪定减轻冠状动脉搭桥术后急性肾功能衰竭：一项前瞻性临床试验

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-08-01 DOI: 10.1016/j.recesp.2024.02.004

{"title":"La dexmedetomidina mitiga la insuficiencia renal aguda tras la cirugía de revascularización coronaria: un ensayo clínico prospectivo","authors":"","doi":"10.1016/j.recesp.2024.02.004","DOIUrl":"10.1016/j.recesp.2024.02.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>To evaluate the impact of dexmedetomidine impact on cardiac surgery-associated acute kidney injury (CSA-AKI), kidney function, and metabolic and oxidative stress in patients undergoing coronary artery bypass grafting with heart-lung machine support.</p></div><div><h3>Methods</h3><p>A randomized double-masked trial with 238 participants (50-75 years) undergoing coronary artery bypass grafting was conducted from January 2021 to December 2022. The participants were divided into Dex (n=119) and NS (n = 119) groups. Dex was administered at 0.5 mcg/kg over 10minutes, then 0.4 mcg/kg/h until the end of surgery; the NS group received equivalent saline. Blood and urine were sampled at various time points pre- and postsurgery. The primary outcome measure was the incidence of CSA-AKI, defined as the occurrence of AKI within 96hours after surgery.</p></div><div><h3>Results</h3><p>The incidence of CSA-AKI was significantly lower in the Dex group than in the NS group (18.26% vs 32.46%; <em>P</em>  <.05) and urine volume 24hours after surgery (<em>P</em>  <.01), blood urea nitrogen level at T3–T6 (<em>P</em>  <.01), and lactate level at T3–T4 (<em>P</em>  <!-->.01).</p></div><div><h3>Conclusions</h3><p>Dex reduces CSA-AKI, potentially by regulating metabolic disorders and reducing oxidative stress.</p><p>Registered with the Chinese Clinical Study Registry (No. ChiCTR2100051804).</p></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 8","pages":"Pages 645-655"},"PeriodicalIF":5.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ecocardiografía transtorácica previa al procedimiento para predecir los resultados de la reparación percutánea de borde a borde en la insuficiencia mitral primaria crónica 术前经胸超声心动图预测慢性原发性二尖瓣反流经皮边缘对边缘修补术的疗效

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-08-01 DOI: 10.1016/j.recesp.2023.12.001

{"title":"Ecocardiografía transtorácica previa al procedimiento para predecir los resultados de la reparación percutánea de borde a borde en la insuficiencia mitral primaria crónica","authors":"","doi":"10.1016/j.recesp.2023.12.001","DOIUrl":"10.1016/j.recesp.2023.12.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Limited data exist on the prognostic usefulness of transthoracic echocardiography preceding MitraClip for chronic primary mitral regurgitation (MR). We evaluated the predictive ability of transthoracic echocardiography in this setting.</p></div><div><h3>Methods</h3><p>A total of 410 patients (median age, 83 years, 60.7% males) were included in the study. The primary outcome was the 1-year composite of all-cause mortality or heart failure hospitalization. Secondary endpoints encompassed individual elements of the primary outcome, the persistence of significant functional impairment or above-moderate MR at 1 year, and above-mild MR at 1-month.</p></div><div><h3>Results</h3><p>The only parameter associated with the risk of the primary outcome was a ventricular end systolic diameter index of ≥ 2.1cm/m2, corresponding to the cohort's 4th quartile (HR, 2.44; 95%CI, 1.09-4.68; P=.022). Concurrently, higher left atrial volume index (LAVi) and a mid-diastolic medial-lateral mitral annular diameter (MAD) equal to or above the cohort's median of 32.2 mm were linked to a higher probability of death and heart failure hospitalization, respectively. LAVi of ≥ 60 mL/m2, above-mild mitral annular calcification, and above-moderate tricuspid regurgitation conferred higher odds of functional class III-IV or above-moderate MR persistence. All variables except LAVi and MAD, as well as indexed mid-diastolic medial-lateral MAD of ≥ 20.2 mm/m2 and mitral effective regurgitant orifice area of ≥ 0.40cm2, were associated with greater-than-mild MR at 1 month.</p></div><div><h3>Conclusions</h3><p>Preprocedural increased indexed left heart dimensions, mainly left ventricular end-systolic diameter index, MAD, mitral annular calcification, mitral effective regurgitant orifice area, and tricuspid regurgitation mark a less favorable course post-MitraClip for chronic primary MR.</p></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 8","pages":"Pages 621-631"},"PeriodicalIF":5.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140276800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registro español de marcapasos. XXI informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2023) 西班牙起搏器登记处。西班牙心脏病学会心律协会第二十一期正式报告（2023 年）。

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-07-24 DOI: 10.1016/j.recesp.2024.07.010

Manuel Molina-Lerma , Rocío Cózar-León , Francisco Javier García-Fernández , David Calvo

{"title":"Registro español de marcapasos. XXI informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2023)","authors":"Manuel Molina-Lerma , Rocío Cózar-León , Francisco Javier García-Fernández , David Calvo","doi":"10.1016/j.recesp.2024.07.010","DOIUrl":"10.1016/j.recesp.2024.07.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Data on implants of cardiac pacing systems in Spain in 2023 are presented.</div></div><div><h3>Methods</h3><div>The registry is based on the information provided by centers to the recording platform of the Heart Rhythm Association after device implantations, through Cardiodispositivos, the online platform of the National Registry. Other information sources include: <em>a)</em> data transfers from the manufacturing and marketing industry; <em>b)</em> the European pacemaker patient card; and <em>c)</em> local databases submitted by the implanting centers.</div></div><div><h3>Results</h3><div>In 2023, 112 hospitals participated in the registry (30 more than in 2022). A total of 24 343 device implantations were reported (48.1% more than in 2022) compared with 45 120 reported by Eucomed (European Confederation of Medical Suppliers Associations). Of these, 1646 were cardiac resynchronization therapy pacemakers. The devices showing the largest increases were leadless pacemakers, with 963 devices implanted, representing an 18.1% increase over 2022. The most frequent indication was atrioventricular block followed, for the first time, by atrial tachyarrhythmia with slow ventricular response. The number of devices included in remote monitoring also increased (cardiac resynchronization therapy defibrillators, 71%; cardiac resynchronization therapy pacemakers, 63%; and conventional pacemakers, 28%), although more moderately.</div></div><div><h3>Conclusions</h3><div>In 2023, there was an increase in the number of institutions participating in the registry. The reporting of device implantations rose by 48.1%, and the implantation of leadless pacemakers grew by 18.1%. Remote monitoring also experienced modest growth compared with previous years.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 11","pages":"Pages 947-956"},"PeriodicalIF":5.9,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141850133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registro español de hemodinámica y cardiología intervencionista. XXXIII informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2023) 西班牙血液动力学和介入心脏病学登记处。西班牙心脏病学会介入心脏病学协会第三十三次正式报告（1990-2023 年）。

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-07-17 DOI: 10.1016/j.recesp.2024.07.005

Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid Álvarez

{"title":"Registro español de hemodinámica y cardiología intervencionista. XXXIII informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2023)","authors":"Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid Álvarez","doi":"10.1016/j.recesp.2024.07.005","DOIUrl":"10.1016/j.recesp.2024.07.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This article presents the 2023 activity report of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).</div></div><div><h3>Methods</h3><div>All interventional cardiology laboratories in Spain were invited to participate in an online survey. Data analysis was carried out by an external company and subsequently reviewed and presented by the members of the ACI-SEC board<em>.</em></div></div><div><h3>Results</h3><div>A total of 119 hospitals participated. The number of diagnostic studies decreased by 1.8%, while the number of percutaneous coronary interventions (PCI) showed a slight increase. There was a reduction in the number of stents used and an increase in the use of drug-coated balloons. The use of intracoronary diagnostic techniques remained stable. For the first time, data on PCI guided by intracoronary imaging was reported, showing a 10% usage rate in Spain. Techniques for plaque modification continued to grow. Primary PCI increased, becoming the predominant treatment for myocardial infarction (97%). Noncoronary structural procedures continued their upward trend. Notably, the number of left atrial appendage closures, patent foramen ovale closures, and tricuspid valve interventions grew in 2023. There was also a significant increase in interventions for acute pulmonary embolism.</div></div><div><h3>Conclusions</h3><div>The 2023 Spanish cardiac catheterization and coronary intervention registry indicates a stabilization in coronary interventions, together with an increase in complexity. There was consistent growth in procedures for both valvular and nonvalvular structural heart diseases.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 11","pages":"Pages 936-946"},"PeriodicalIF":5.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141853753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rest in PEACE? 安息？

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2024.01.007

Raban V. Jeger, Gregor Fahrni

引用次数: 0

En reconocimiento del origen español del CRISPR/Cas9. Implicaciones para el tratamiento de las cardiopatías familiares. Respuesta 纪念 CRISPR/Cas9 的西班牙起源。对治疗家族性心脏病的意义。回应

IF 5.9 2区医学

Revista espanola de cardiologia Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2024.03.014

Alessia Argirò , Jeffrey Ding , Eric Adler

引用次数: 0

PET-TC con [18F]-fluorodesoxiglucosa en amiloidosis sistémica con afección cardiaca 18F]-氟脱氧葡萄糖 PET-CT 在心脏受累的全身性淀粉样变性中的应用